(268 days)
The Avelle™ NPWT System is indicated for use on patients that would benefit from a Negative Pressure Wound Therapy (NPWT) device as it may promote wound healing via removal of exudate and infectious materials from low to moderately exuding wound, such as:
- · Chronic Wounds e.g. Leg ulcers
- · Acute Wounds
- · Subacute and dehisced wounds
- Traumatic wounds
- · Flaps & Grafts
- · Surgically closed incision sites
Avelle™ NPWT System is suitable for use in a hospital, post-acute and home health environment.
The Avelle Negative Pressure Wound Therapy (NPWT) System consists of:
- a disposable battery powered pump
- absorbent wound dressing which is connected to the pump via tubing and luer-lock fittings
- adhesive fixation strips
The Avelle System is intended for single-patient use.
The Avelle pump is disposable, portable and battery-powered. The internal software of the pump limits the use to 30 days. The pump requires 3 AAA lithium batteries to operate. Testing shows that the 3 batteries will power the pump for a minimum of 15.6 days based on testing. A total of 6 AAA lithium batteries (2 sets) are provided with the pump which will power the device for its entire 30-day lifetime. The disposable battery-powered pump unit is attached to the dressing via the supplied tubing and luer-lock fittings.
The Avelle dressing is comprised of gelling fiber (Hydrofiber®) to absorb wound exudate with negative pressure applied indirectly to the dressing via the Avelle pump. The dressing is applied to the wound and secured around its periphery via its adhesive border and adhesive fixation strips are applied to ensure an adequate seal. The dressing's adhesive surface is protected by a split release liner system comprising of 2 or 3 sections of Low Density Polyethylene (LDPE) release liner (depending on dressing size), which are removed prior to dressing application.
The pump is turned on to apply and maintain a nominal negative pressure of -80mmHg to the dressing. The pump will draw excess wound exudate and infectious materials away from the wound bed and into the Hydrofiber® layers as demonstrated in a simulated use test with a moderately exuding flow of 82 mL over 3 days and a second simulated use test with a low exuding flow of 102 mL over 7 days.
The system will deliver up to 30 days' single patient use for the pump component, and up to 7 days' wear time for the dressing. Each dressing may be used for up to 7 days but may require more frequent changes due to clinical situations. After 30 days of use the pump must be discarded and treatment must be stopped.
The pump unit is provided non-sterile. The Absorbing Dressing (with adhesive fixation strips) is provided sterile via ethylene oxide (EtO) sterilization.
This document, a 510(k) summary for the AVELLE Negative Pressure Wound Therapy System, describes non-clinical performance testing rather than clinical studies with human participants. Therefore, many of the requested elements for clinical study data (such as sample size for test sets, ground truth establishment for test sets, expert qualifications, adjudication methods, and MRMC studies) are not applicable.
Here's a breakdown of the available information:
1. Table of Acceptance Criteria and Reported Device Performance
The document summarizes that "The AVELLE NPWT meets all the requirements for overall design, sterilization, biocompatibility, and electrical safety results confirming that the design output meets the design inputs and specifications for the device." Specific quantitative acceptance criteria are not provided in this summary, but the successful completion of the listed tests implies that the device met their pre-defined criteria.
| Test Category | Acceptance Criteria (Implied) | Reported Device Performance |
|---|---|---|
| Overall Design | Met design inputs/specs | Met requirements |
| Sterilization | Met design inputs/specs | Met requirements (Absorbing Dressing is provided sterile via ethylene oxide (EtO) sterilization) |
| Biocompatibility | Met design inputs/specs | Met requirements |
| Electrical Safety | Met design inputs/specs | Met requirements |
| Peel testing (dressing) | Met design inputs/specs | Successfully completed |
| Peel testing (fixation strips) | Met design inputs/specs | Successfully completed |
| Bacterial Barrier testing | Met design inputs/specs | Successfully completed |
| Viral penetration testing | Met design inputs/specs | Successfully completed |
| Distribution of Negative pressure | Met design inputs/specs | Successfully completed; nominal negative pressure of -80mmHg applied |
| Absorption assessment | Met design inputs/specs | Successfully completed; system draws excess wound exudate and infectious materials away from wound bed and into Hydrofiber® layers |
| Fluid Retention testing | Met design inputs/specs | Successfully completed |
| Moisture Vapor Transmission Rate | Met design inputs/specs | Successfully completed |
| Pump performance & alarm testing | Met design inputs/specs | Successfully completed; pump powers for a minimum of 15.6 days with 3 AAA lithium batteries, total 30-day lifetime with 6 batteries (2 sets). |
| Assessing Waterproofness | Met design inputs/specs | Successfully completed |
| Rucking Test | Met design inputs/specs | Successfully completed |
| Simulated Use Testing | Met design inputs/specs | Successfully completed: demonstrated removal of exudate and infectious materials with a moderately exuding flow of 82 mL over 3 days and a low exuding flow of 102 mL over 7 days. |
| Human Factors/Usability Testing | Met design inputs/specs | Successfully completed |
| Software Documentation | Met FDA guidance | Assembled according to recommendations in "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices" (May 11, 2005). Software Level of Concern determined to be Moderate. |
2. Sample size used for the test set and the data provenance
The document does not specify exact sample sizes for each non-clinical test. The tests are "bench testing" and "simulated use tests," meaning they were conducted in a laboratory setting, not on human patients. The data provenance is ConvaTec Limited (the applicant).
3. Number of experts used to establish the ground truth for the test set and their qualifications
Not applicable. These were non-clinical, bench and simulated use tests, not diagnostic studies requiring expert review for ground truth.
4. Adjudication method for the test set
Not applicable for non-clinical bench testing.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
Not applicable. This is a medical device (NPWT system), not an AI-powered diagnostic tool, and no MRMC study was conducted or mentioned. The document explicitly states "Clinical Data is not included in this 510(k)."
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done
The device is a physical system (pump, dressing, tubing), not an algorithm-only device. "Standalone" performance would refer to the device's functional operation, which was assessed through the various bench and simulated use tests.
7. The type of ground truth used
For the non-clinical tests, the "ground truth" was established by engineering specifications, validated test methods, and industry standards for material properties, sterility, performance, and safety. For example, bacterial barrier testing would have a known standard for barrier effectiveness as its "ground truth."
8. The sample size for the training set
Not applicable. This is a physical medical device, not a machine learning model requiring a training set.
9. How the ground truth for the training set was established
Not applicable for the same reason as above.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
October 19, 2018
ConvaTec Limited Justin Lovelace Senior Regulatory Affairs Specialist First Avenue Deeside, CH5 2NU Gb
Re: K180205
Trade/Device Name: AVELLE Negative Pressure Wound Therapy System Regulation Number: 21 CFR 878.4780 Regulation Name: Powered Suction Pump Regulatory Class: Class II Product Code: OMP Dated: September 14, 2018 Received: September 17, 2018
Dear Justin Lovelace:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
{1}------------------------------------------------
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products, and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
for
Image /page/1/Picture/5 description: The image shows the name "Cynthia Chang -S" in a large, sans-serif font. The text is black and appears to be centered on a white background. The letters are clear and easy to read, with consistent spacing between them.
Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K180205
Device Name
Avelle™ Negative Pressure Wound Therapy System
Indications for Use (Describe)
The Avelle™ NPWT System is indicated for use on patients that would benefit from a Negative Pressure Wound Therapy (NPWT) device as it may promote wound healing via removal of exudate and infectious materials from low to moderately exuding wound, such as:
- · Chronic Wounds e.g. Leg ulcers
- · Acute Wounds
- · Subacute and dehisced wounds
- Traumatic wounds
- · Flaps & Grafts
- · Surgically closed incision sites
Avelle™ NPWT System is suitable for use in a hospital, post-acute and home health environment.
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
K180205 - 510(k) Summary
| Device: | Avelle Negative Pressure Wound Therapy System |
|---|---|
| Applicant: | ConvaTec Limited |
| Contact: | Justin LovelaceSenior Regulatory Affairs SpecialistTelephone: 1-336-542-4745Email: Justin.Lovelace@convatec.com |
| Date: | October 18, 2018 |
| Trade Name: | Avelle Negative Pressure Wound Therapy System |
| Classification Name: | Powered Suction Pump (21 CFR 878.4780) |
| Device Class: | Class II |
| Product Code: | OMP |
Predicate Device Information
| Predicate Device | 510(k) number | Clearance Date |
|---|---|---|
| PICO Single UseNegative PressureWound TherapySystem | K151436 | 01/28/2016 |
Device Description:
The Avelle Negative Pressure Wound Therapy (NPWT) System consists of:
- a disposable battery powered pump ।
- absorbent wound dressing which is connected to the pump via tubing and luer-lock fittings
- adhesive fixation strips
The Avelle System is intended for single-patient use.
The Avelle pump is disposable, portable and battery-powered. The internal software of the pump limits the use to 30 days. The pump requires 3 AAA lithium batteries to operate. Testing shows that the 3 batteries will power the pump for a minimum of 15.6 days based on testing. A total of 6 AAA lithium batteries (2 sets) are provided with the pump which will power the device
{4}------------------------------------------------
for its entire 30-day lifetime. The disposable battery-powered pump unit is attached to the dressing via the supplied tubing and luer-lock fittings.
The Avelle dressing is comprised of gelling fiber (Hydrofiber®) to absorb wound exudate with negative pressure applied indirectly to the dressing via the Avelle pump. The dressing is applied to the wound and secured around its periphery via its adhesive border and adhesive fixation strips are applied to ensure an adequate seal. The dressing's adhesive surface is protected by a split release liner system comprising of 2 or 3 sections of Low Density Polyethylene (LDPE) release liner (depending on dressing size), which are removed prior to dressing application.
The pump is turned on to apply and maintain a nominal negative pressure of -80mmHg to the dressing. The pump will draw excess wound exudate and infectious materials away from the wound bed and into the Hydrofiber® layers as demonstrated in a simulated use test with a moderately exuding flow of 82 mL over 3 days and a second simulated use test with a low exuding flow of 102 mL over 7 days.
The system will deliver up to 30 days' single patient use for the pump component, and up to 7 days' wear time for the dressing. Each dressing may be used for up to 7 days but may require more frequent changes due to clinical situations. After 30 days of use the pump must be discarded and treatment must be stopped.
The pump unit is provided non-sterile. The Absorbing Dressing (with adhesive fixation strips) is provided sterile via ethylene oxide (EtO) sterilization.
Indications for Use
The Avelle™ NPWT System is indicated for use on patients that would benefit from a Negative Pressure Wound Therapy (NPWT) device as it may promote wound healing via removal of exudate and infectious materials from low to moderately exuding wound, such as:
- Chronic Wounds e.g. Leg ulcers
- Acute Wounds
- Subacute and dehisced wounds
- Traumatic wounds
- Flaps & Grafts
- Surgically closed incision sites
Avelle™ NPWT System is suitable for use in a hospital, post-acute and home health environment.
Clinical Data Clinical Data is not included in this 510(k).
{5}------------------------------------------------
Non-Clinical Performance Data
The AVELLE NPWT is subject to a number of non-clinical performance tests. The AVELLE NPWT meets all the requirements for overall design, sterilization, biocompatibility, and electrical safety results confirming that the design output meets the design inputs and specifications for the device.
The list below summarizes the bench testing undertaken and successfully completed for the AVELLE NPWT system:
- Peel testing of the dressing
- Peel testing of the adhesive fixation strips ●
- Bacterial Barrier testing
- Viral penetration testing
- Distribution of Negative pressure across the dressing
- Absorption assessment of dressing ●
- Fluid Retention testing
- Moisture Vapor Transmission Rate assessment of dressing
- Pump performance and alarm testing
- Assessing Waterproofness
- Rucking Test of the adhesive strips
- Simulated Use Testing
- . Human Factors/Usability Testing
The software documentation in this submission has been assembled according to the recommendations in the FDA document, Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices, dated May 11, 2005. The software Level of Concern has been evaluated and determined to be Moderate, and appropriate documentation included, as recommended by the cited FDA guidance.
Conclusions
In establishing substantial equivalence to the predicate device, ConvaTec evaluated the indications for use, materials, technology, product specifications, and performance of the device and determined the subject device is substantially equivalent to the predicate. The differences do not raise different questions of safety or effectiveness.
§ 878.4780 Powered suction pump.
(a)
Identification. A powered suction pump is a portable, AC-powered or compressed air-powered device intended to be used to remove infectious materials from wounds or fluids from a patient's airway or respiratory support system. The device may be used during surgery in the operating room or at the patient's bedside. The device may include a microbial filter.(b)
Classification. Class II.